Payment overview · 2025
General Payments
$218.89
11 reported records · 9 companies
Healthcare provider profile · identity verified
Richard P Murray, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEXINGTON, SC · NPI 1013928407
Verified facts
What the public records show
CMS Open Payments records show Richard P Murray, MD received $218.89 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.66 | 16.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $33.45 | 15.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.68 | 13.6% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $27.78 | 12.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.73 | 10.4% | 1 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $20.68 | 9.4% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $19.24 | 8.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.97 | 6.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.70 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $218.89 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.68 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $27.78 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $19.24 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
132 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 68 |
| Omeprazole | Omeprazole | 338 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 329 | 84 |
| Amlodipine Besylate | Amlodipine Besylate | 307 | 79 |
| Lisinopril | Lisinopril | 268 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 236 | 48 |
| Gabapentin | Gabapentin | 231 | 49 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 45 |
| Simvastatin | Simvastatin | 189 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 46 |
| Potassium Chloride | Potassium Chloride | 162 | 35 |
| Losartan Potassium | Losartan Potassium | 156 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 37 |
| Eliquis | Apixaban | 132 | 27 |
| Trazodone Hcl | Trazodone Hcl | 126 | 25 |
| Lorazepam | Lorazepam | 124 | 39 |
| Furosemide | Furosemide | 113 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 95 | 27 |
| Sertraline Hcl | Sertraline Hcl | 93 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 29 |
| Felodipine Er | Felodipine | 91 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 14 |
| Tramadol Hcl | Tramadol Hcl | 88 | 35 |
| Metformin Hcl | Metformin Hcl | 87 | 31 |
| Metformin Hcl Er | Metformin Hcl | 82 | 19 |
| Allopurinol | Allopurinol | 81 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 19 |
| Clonazepam | Clonazepam | 74 | 14 |
| Alprazolam | Alprazolam | 73 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 16 |
| Bupropion Xl | Bupropion Hcl | 72 | 15 |
| Jardiance | Empagliflozin | 68 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 17 |
| Donepezil Hcl | Donepezil Hcl | 67 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 65 | 27 |
| Carvedilol | Carvedilol | 64 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 51 |
| Prednisone | Prednisone | 63 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 12 |
| Mirtazapine | Mirtazapine | 53 | 16 |
| Alendronate Sodium | Alendronate Sodium | 52 | 16 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 15 |
| Xarelto | Rivaroxaban | 47 | 11 |
| Glipizide | Glipizide | 44 | 15 |
| Famotidine | Famotidine | 40 | suppressed |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Ozempic | Semaglutide | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 36 | 25 |
| Finasteride | Finasteride | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 31 | 11 |
| Diazepam | Diazepam | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | 11 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Lactulose | Lactulose | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 13 |
| Atenolol | Atenolol | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 24 | 16 |
| Ezetimibe | Ezetimibe | 24 | 12 |
| Ondansetron Odt | Ondansetron | 24 | 13 |
| Linzess | Linaclotide | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Novolog | Insulin Aspart | 18 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 17 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Silodosin | Silodosin | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | 11 |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Enbrel Sureclick | Etanercept | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $218.89 · 11 records | Novo Nordisk Inc | AREXVY, CLOTTRIEVER BOLD CATHETER, CeQur Simplicity, Dexcom G6 Transmitter, INJECTAFER, NURTEC ODT, Ozempic, SHINGRIX, VRAYLAR, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error